论文部分内容阅读
目的观察比较倍他乐克在治疗慢性心衰病人中的疗效。方法146例慢性心衰患者随机分成两组,一组给予倍他乐克6.25 mg,口服,每天2次;另一组为空白对照,给予安慰剂,口服,每天2次,疗程均为1个月。结果两组采用不同药物治疗的患者群体短期死亡率方面χ2=0.098,P>0.05,两样本率间差异没有统计学意义;在1年内并发症出现率χ2=3.982,P<0.05,长期预后方面χ2=4.419,P<0.05,差异有统计学意义。结论小剂量倍他乐克选择性阻断β1受体,降低心肌的耗氧量,对抗儿茶酚胺的心脏毒性作用,在改善症状、防止并发症、改善患者长期预后等方面,倍他乐克要优于对照组。
Objective To compare the efficacy of metoprolol in the treatment of patients with chronic heart failure. Methods A total of 146 patients with chronic heart failure were randomly divided into two groups: one group received Betaloc 6.25 mg orally twice a day; the other group as blank control, placebo orally twice a day for one course of treatment month. Results There was no significant difference in the short-term mortality between the two groups (χ2 = 0.098, P> 0.05). There was no significant difference between two groups in the short-term mortality rate. The incidence of complications in one year χ2 = 3.982, P <0.05, χ2 = 4.419, P <0.05, the difference was statistically significant. Conclusion Betametacl can selectively block β1 receptor, reduce myocardial oxygen consumption, antagonize the cardiotoxic effect of catecholamines, and improve the symptoms, prevent complications and improve patients’ long-term prognosis In the control group.